论文部分内容阅读
对原发性支气管癌手术后的病人,用左旋咪唑治疗以测定其促进免疫的作用。患者在手术前三天开始口服左旋咪唑或安慰剂,每日三次,每次50毫克,每两周连服三天。除非临床出现复发,均禁用细胞抑制性药物、肾上腺皮质激素和放射疗法。对111例病人随访一年,发现两组的副作用发生率相似。左旋咪唑组51例中有10例复发(7例死亡)。安慰剂组60例中有20例复发(12例死亡)。进一步分析表明:鳞状细胞癌、中等的和大的原发性肿瘤用左旋咪唑者复发较少。在扩散性肿瘤病人中用左旋咪唑者,由于
In patients with primary bronchial carcinoma after surgery, levamisole was administered to determine its role in promoting immunity. Patients started oral levamisole or placebo three days prior to surgery three times a day for 50 mg twice daily for three days. Unless clinically relapsed, cytostatics, adrenocortical hormones, and radiation therapy are disabled. Follow-up of 111 patients a year and found that the incidence of side effects in both groups were similar. Ten of the 51 patients in the levamisole group relapsed (7 deaths). Twenty of the 60 placebo patients relapsed (12 deaths). Further analysis showed that: squamous cell carcinoma, medium and large primary tumors with levamisole less recurrence. Levamisole in patients with diffuse tumors, due to